What is AOD 9604?
AOD 9604 is a synthetic peptide containing a modified C-terminal fragment of human Growth Hormone (specifically residues 177-191, with an added tyrosine at the N-terminus for stability). It was originally developed to capture the fat-burning (lipolytic) properties of growth hormone without triggering the unwanted side effects associated with full-length hGH, such as insulin resistance or cellular proliferation.
How does AOD 9604 work?
AOD 9604 stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the formation of new fat) by targeting beta-3 adrenergic receptors, which are highly expressed in adipose tissue. Unlike full-length hGH, it does not bind to the growth hormone receptor or stimulate Insulin-Like Growth Factor 1 (IGF-1) production. This selective pathway allows it to target fat tissue without altering blood glucose levels or promoting systemic cellular growth.
Primary Documented Uses
- Targeted reduction of localized adipose (fat) tissue
- Stimulating metabolic rate and fat oxidation
- Experimental cartilage and joint repair therapies
Research Summary
Pre-clinical and early clinical trials suggest that AOD 9604 is well-tolerated and promotes moderate fat loss, particularly in abdominal regions. However, larger human clinical trials for obesity did not show robust, statistically significant long-term weight loss compared to placebo, leading to the suspension of its development as a primary pharmaceutical weight-loss drug. Interestingly, recent animal research has explored its potential to stimulate cartilage repair in osteoarthritic joints.
Legal and Regulatory Status
AOD 9604 is not approved by the FDA for human use. In late 2023, the FDA classified AOD 9604 as a Category 2 bulk drug substance, restricting compounding pharmacies from preparing it due to safety and efficacy concerns. It is legally classified as a research chemical.
Frequently Asked Questions
What is AOD 9604?
AOD 9604 is A synthetic peptide fragment of human Growth Hormone designed to stimulate fat breakdown without affecting blood sugar or cellular growth.
How does AOD 9604 work?
AOD 9604 stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the formation of new fat) by targeting beta-3 adrenergic receptors, which are highly expressed in adipose tissue. Unlike full-length hGH, it does not bind to the growth hormone receptor or stimulate Insulin-Like Growth Factor 1 (IGF-1) production. This selective pathway allows it to target fat tissue without altering blood glucose levels or promoting systemic cellular growth.
What does research say about AOD 9604?
Pre-clinical and early clinical trials suggest that AOD 9604 is well-tolerated and promotes moderate fat loss, particularly in abdominal regions. However, larger human clinical trials for obesity did not show robust, statistically significant long-term weight loss compared to placebo, leading to the suspension of its development as a primary pharmaceutical weight-loss drug. Interestingly, recent animal research has explored its potential to stimulate cartilage repair in osteoarthritic joints.
Is AOD 9604 FDA-approved or legally available?
AOD 9604 is not approved by the FDA for human use. In late 2023, the FDA classified AOD 9604 as a Category 2 bulk drug substance, restricting compounding pharmacies from preparing it due to safety and efficacy concerns. It is legally classified as a research chemical.